|
| Press Releases |
|
 |
|
| Thursday, March 20, 2025 |
|
|
Sino Biopharm (1177.HK) Announces 2024 Annual Results |
| Sino Biopharmaceutical Limited ('Sino Biopharm' or the 'Company', together with its subsidiaries, the 'Group') (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2024. more info >> |
|
| Wednesday, August 14, 2024 |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results |
| Sino Biopharmaceutical Limited (?Sino Biopharmaceutical? or the ?Company?, together with its subsidiaries, the ?Group?) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the ?Period?). more info >> |
|
| Friday, March 29, 2024 |
|
|
Sino Biopharm (1177.HK) Announces 2023 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2023. more info >> |
|
| Friday, August 25, 2023 |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period"). more info >> |
|
| Friday, March 31, 2023 |
|
|
Sino Biopharm (1177.HK) Announces 2022 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022. more info >> |
|
| Tuesday, August 23, 2022 |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited Interim results for the six months ended 30 June 2022 (the "Period"). more info >> |
|
| Thursday, July 22, 2021 |
|
|
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic. more info >> |
|
| Monday, May 24, 2021 |
|
|
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021. more info >> |
|
| Tuesday, March 23, 2021 |
|
|
Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited annual results for the year ended 31 December 2020. more info >> |
|
| Monday, December 7, 2020 |
|
|
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., Ltd. ("Sinovac LS", previously known as Sinovac Research and Development Co., Ltd.), which will be funded by internal resources of the Group and result in a 15.03% equity interest in Sinovac LS. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
JCB Brings Apple Pay to Cardmembers in Vietnam
Jul 1, 2025 11:15 JST
|
|
|
First Shipment of LNG from the LNG Canada Project 
Jul 1, 2025 11:00 JST
|
|
|
Chinabank Fully Transitions Into AI-powered Human Capital Management
Jul 1, 2025 08:00 HKT/SGT
|
|
|
HKIRA Announces Winners of the 11th IR Awards 2025
Jul 1, 2025 00:20 HKT/SGT
|
|
|
Eagle Football Holdings supports Leadership Changes at Olympique Lyonnais
Jun 30, 2025 20:01 HKT/SGT
|
|
|
Approval in Principle (AiP) for World's First LCO2 / Methanol Carrier
Jun 30, 2025 20:30 JST
|
|
|
Acropolis Rally Greece: Day 4 Sunday success and second overall for TOYOTA GAZOO Racing's Ogier
Jun 30, 2025 20:15 JST
|
|
|
Mitsubishi Fuso-Hino Merger: 4 Firms Collaborate for the Future of Commercial Vehicles
Jun 30, 2025 20:10 JST
|
|
|
Six Companies Establish BlueRebirth Council to Expand Use of Recycled Materials in New Vehicles
Jun 30, 2025 19:25 JST
|
|
|
Honda Changes Plan to Build New Production Plant for Next-generation Fuel Cell Module in Japan
Jun 30, 2025 19:20 JST
|
|
|
MHI-AC&R Receives Recommendation Award of JARAC's 42nd Excellent Energy Saving Equipment Awards
Jun 30, 2025 19:00 JST
|
|
|
Ten innovative youth-led housing solutions win a total of US$40,000 in grants from Habitat for Humanity
Jun 30, 2025 12:28 HKT/SGT
|
|
|
The University of Osaka and Fujitsu Japan launch joint research on AI-powered education support for culturally and linguistically diverse children in Japan
Jun 30, 2025 12:00 JST
|
|
|
JCB has launched contactless subway payment services in Shanghai and Beijing, marking the first such service in mainland China
Jun 30, 2025 12:00 JST
|
|
|
Chagee's Global Potential Far Outpaces Its 15x PE Valuation
Jun 30, 2025 10:06 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
